Regeneron Pharmaceuticals REGN announced that the FDA has approved extending dosing intervals of up to every 20 weeks for ...

The stock is one of only two in IBD's biotech group with highest-possible 99 Composite Ratings.

Regeneron (REGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain ...

Regeneron Pharmaceuticals (REGN) is back in focus after Japan approved Dupixent as the first targeted treatment for adults ...

Piper Sandler starts Regeneron at overweight with $875 price target, citing Dupixent growth and pipeline catalysts. Read more ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Jim Cramer’s Hottest GLP-1 and Weight Loss Stock Picks. For more stocks, you can head to Jim Cramer’s Hottest GLP-1 and Weight Loss Stock Picks: Top 5 Stocks. In an appearance on CNBC’s Fast Money in ...

Regeneron (REGN +0.93%) has encountered several headwinds over the past two years, including the loss of patent exclusivity ...

President Trump said Monday that the US and Iran had held "productive" talks and called off strikes. Oil dropped, and stocks rose, but pared some gains after Iran pushed back on Trump's comments. US ...

Oil prices rose Sunday after Iran threatened to shut down the Strait of Hormuz indefinitely in response to President Donald Trump’s ultimatum on the restoration of oil traffic through the critical ...

Stocks tumbled in volatile trading Friday as the U.S.-Israel conflict with Iran showed no sign of abating and oil prices continued their ascent. The Dow Jones Industrial average shed 443.96 points, or ...